2. Neurocrine Biosciences Inc. (NASDAQ:NBIX)
Neurocrine Biosciences, Inc. (NASDAQ: NBIX) is one of the strongest large-cap biotech stocks on this list because it combines commercial scale, neuroscience specialization, rare-disease expansion, and strong earnings power. Based on latest market data, Neurocrine traded at $158.42, with a market capitalization of about $16.38 billion and a P/E ratio near 24.37. In the uploaded screen, Neurocrine also stood out with a 23.16% 12-week price change, a forward P/E of 17.32, projected one-year EPS growth of 43.13%, and projected sales growth of 29.58%. That is the kind of setup investors like to see in biotech: not just pipeline hype, but actual commercial acceleration.
The company’s Q1 2026 report was strong. Neurocrine delivered total first-quarter 2026 net product sales of $811.0 million, up 44% year over year. INGREZZA net product sales reached $656.9 million, up 20%, while CRENESSITY contributed $153.3 million, showing a meaningful launch ramp. Total revenue rose to $814.5 million from $572.6 million in the prior-year period. Neurocrine also reaffirmed full-year 2026 INGREZZA net sales guidance of $2.7 billion to $2.8 billion, which gives investors a clearer anchor for the year.
CEO Kyle W. Gano said Neurocrine’s “strong first-quarter performance reflects continued momentum across our commercial portfolio” as the company diversifies across therapeutic areas. That diversification point is critical. Neurocrine is no longer just an INGREZZA story; CRENESSITY is becoming more important, and the company also announced a definitive agreement to acquire Soleno Therapeutics, including VYKAT XR for hyperphagia in Prader-Willi syndrome. Reuters reported that the Soleno deal is valued at about $2.9 billion, giving Neurocrine another rare-disease commercial asset. The risk is that Neurocrine still depends heavily on INGREZZA durability, while the Soleno transaction adds integration and execution risk. But for investors looking for a biotech stock with actual product demand, expanding rare-disease exposure, and visible revenue momentum, NBIX remains one of the most serious names in the sector.
Click next to see the following stock...
